BriaCell Therapeutics - Warrants (24/02/2025) Operating Income

BriaCell Therapeutics - Warrants (24/02/2025) (BCTXW) currently reports a operating income of $-31M as of July 2026. That compares with $-280 in the prior-year period — down 11103508.0% year over year. Use the charts on this page to explore BriaCell Therapeutics - Warrants (24/02/2025)'s operating income history and peer comparisons.

BriaCell Therapeutics - Warrants (24/02/2025)'s operating income decreased from $-280 to $-31M — a 11103508.0% year-over-year decrease (period ending July 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BriaCell Therapeutics - Warrants (24/02/2025) reported $-31M in operating income as of July 2026. That compares with $-280 in the prior-year period — down 11103508.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-31M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BriaCell Therapeutics - Warrants (24/02/2025), and consider following BCTXW for alerts when major investors trade the stock.

BriaCell Therapeutics - Warrants (24/02/2025) is classified in the Healthcare sector. On operating income, it currently shows $-31M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BCTXW with unrelated industries.